Last 29.15 INR
Change Today -0.35 / -1.19%
Volume 672.7K
KOP On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

kopran ltd (KOP) Snapshot

Open
29.75
Previous Close
29.50
Day High
30.65
Day Low
28.65
52 Week High
04/22/14 - 30.95
52 Week Low
06/25/13 - 12.00
Market Cap
1.1B
Average Volume 10 Days
484.3K
EPS TTM
2.85
Shares Outstanding
39.1M
EX-Date
09/11/00
P/E TM
10.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for KOPRAN LTD (KOP)

Related News

No related news articles were found.

kopran ltd (KOP) Related Businessweek News

No Related Businessweek News Found

kopran ltd (KOP) Details

Kopran Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and finished dosage forms. The company offers APIs that include oral and sterile cephalosporins, macrolides, and neuromodulators, as well as cardiovascular drugs. Its finished dosage forms consists of anthelmintics, anti allergics, antibiotics, anti fungal, pain management, anti pyretic, respiratory, diabetic, cardiovascular, and gastroenterology products, as well as drugs for erectile dysfunction. The company offers these products in various dosage forms comprising tablets, capsules, dry powder, suspension, and injectables. The company was incorporated in 1958 and is based in Mumbai, India.

Founded in 1958

kopran ltd (KOP) Top Compensated Officers

Chief Operating Officer and Whole-Time Direct...
Total Annual Compensation: 5.7M
Executive Vice Chairman, Member of Audit Comm...
Total Annual Compensation: 3.0M
Compensation as of Fiscal Year 2013.

kopran ltd (KOP) Key Developments

Kopran Limited Receives Approval for the Finished Dosage Forms Facility

Kopran Limited has announced that the United Kingdom, Medicines and Healthcare products Regulatory Agency (UKMHRA) has granted the Certificate of Compliance with principles and guidelines of Good Manufacturing Practice for the Finished Dosage Forms facility located at Savroli, Khalapur, Khopoli manufacturing general capsules arid tablets. The approval for this facility shall enable the Company to supply Finished Dosage Forms to the UK and the European market for which necessary marketing tie-ups are being entered into. The facility also has approvals from Regulatory Authorities of several countries all over the world including the Medicines Control Council, South Africa (MCC) and the Therapeutic Goods Administration, Australia (TGA).

Kopran Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

Kopran Limited reported unaudited earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the company reported net sales of INR 762.8 million against INR 563.3 million a year ago. Profit from operations before other income, interest and exceptional items was INR 64.9 million against INR 39.2 million a year ago. Profit before tax was INR 30.7 million against INR 22.6 million a year ago. Net profit for the period was INR 30.7 million against INR 22.6 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 0.79 against INR 0.58 a year ago. For the nine months, the company reported net sales of INR 2,129.2 million against INR 1,689.1 million a year ago. Profit from operations before other income, interest and exceptional items was INR 226.8 million against INR 150.4 million a year ago. Profit before tax was INR 108.9 million against INR 80.0 million a year ago. Net profit for the period was INR 108.9 million against INR 80.0 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 2.79 against INR 2.05 a year ago.

Kopran Limited to Report Q3, 2014 Results on Feb 13, 2014

Kopran Limited announced that they will report Q3, 2014 results on Feb 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KOP:IN 29.15 INR -0.35

KOP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KOP.
View Industry Companies
 

Industry Analysis

KOP

Industry Average

Valuation KOP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KOPRAN LTD, please visit www.kopran.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.